In support of innovation and more food choices for consumers, today the U.S.
Food and Drug Administration (FDA) issued a guidance for industry that
describes how firms can voluntarily engage with the FDA before marketing
food from genome-edited plants. The guidance reaffirms that the risk-based
approach the FDA has taken for foods derived from new plant varieties also
applies to foods from genome-edited plants. In addition, this guidance
describes two processes through which they may voluntarily inform the FDA of
the steps they have taken to ensure the safety of foods from their
genome-edited plant varieties: voluntary premarket consultations and
voluntary premarket meetings.



[www.fda.gov]
tary-premarket-engagement-foods-derived-plants-produced-using-genome